down arrow

Guj. Themis Bio.

  • Market Cap: Small Cap
  • Industry: Pharmaceuticals & Drugs
  • ISIN: INE942C01045
  • NSEID: GUJTHEM
  • BSEID: 506879
INR
267.05
20.15 (8.16%)
BSENSE

Apr 11, 12:53 PM

BSE+NSE Vol: 1.01 lacs

Click here to access the older version
  • Price Points
  • Score
  • Mojo Parameters
  • Total Return
  • News and Corporate Actions
  • Key factors
  • Shareholding
  • Financials
  • CompanyCV
stock-summaryPrice Point
High/Low

1Day

251.55272.00

52 Week

192.35390.00
Valuation
Technical
Day's Volume

CASH

1.01 lacs (16.16%) Volume

Shareholding (Feb 2025)

FII

1.47%

Held by 8 FIIs

DII

1.18%

Held by 1 DIIs

Promoter

70.86%

iScoreScore
Click here to find our call on this stock
Strong Sell
Sell
Hold
Buy
Strong Buy
Dashboard
1

Flat results in Dec 24

  • NO KEY NEGATIVE TRIGGERS
2

Stock is technically in a Bearish range

3

With ROE of 23.6, it has a Very Expensive valuation with a 12 Price to Book Value

stock-summaryMojo Parameters
Mojo Parameters
Loading Valuation Snapshot...
Stock DNA
stock-summary
Industry

Pharmaceuticals & Drugs

stock-summary
Market cap

INR 2,910 Cr (Small Cap)

stock-summary
P/E

51.00

stock-summary
Industry P/E

33

stock-summary
Dividend Yield

0.07%

stock-summary
Debt Equity

-0.03

stock-summary
Return on Equity

23.57%

stock-summary
Price to Book

12.04

Revenue and Profits (1 Year):
Net Sales:
40 Cr
(Quarterly Results - Dec 2024)
Net Profit:
13 Cr
stock-summaryTotal Returns
Total Returns (Price + Dividend) stock-summary
Dividend Yield (0.07%)
TimePeriod
Price Return
Dividend Return
Total Return
6 Months
-21.92%
0%
-21.92%
1 Year
1.56%
0.09%
1.65%
2 Years
195.3%
1.96%
197.26%
3 Years
377.26%
20.40%
397.66%
4 Years
809.87%
39.54%
849.41%
5 Years
1532.85%
69.34%
1602.19%

Latest dividend: 0.25 per share ex-dividend date: Jul-15-2024

Risk Adjusted Returns v/s Sensex stock-summary
Returns Beta
Icon
Beta has not been calculated since enough price history is not available
stock-summaryKey Factors
Quality key factors stock-summary
Factor
Value
Sales Growth (5y)
17.53%
EBIT Growth (5y)
29.43%
EBIT to Interest (avg)
60.45
Debt to EBITDA (avg)
0.11
Net Debt to Equity (avg)
0
Sales to Capital Employed (avg)
1.23
Tax Ratio
25.18%
Dividend Payout Ratio
36.63%
Pledged Shares
3.30%
Institutional Holding
2.65%
ROCE (avg)
55.97%
ROE (avg)
42.39%
Valuation key factors
Factor
Value
P/E Ratio
51
Industry P/E
33
Price to Book Value
12.04
EV to EBIT
39.09
EV to EBITDA
36.40
EV to Capital Employed
12.38
EV to Sales
17.30
PEG Ratio
NA
Dividend Yield
0.07%
ROCE (Latest)
31.40%
ROE (Latest)
23.57%
Tecnicals key factors
Indicator
Weekly
Monthly
MACD
Bearish
Mildly Bearish
RSI
No Signal
No Signal
Bollinger Bands
Bearish
Bearish
Moving Averages
Bearish (Daily)
KST
Bearish
Mildly Bearish
Dow Theory
Mildly Bullish
No Trend
OBV
No Trend
Bullish
stock-summary Technical Indicator Scale: Bearish, Mildly Bearish, Sideways, Mildly Bullish, Bullish  Turned 
stock-summaryShareholding
Shareholding Snapshot : Feb 2025stock-summary
Shareholding Compare (%holding) stock-summary
Majority shareholders

Promoters

Pledged Promoter Holdings

3.3023

Mutual Funds

Held by 5 Schemes (1.16%)

FIIs

Held by 8 FIIs (1.47%)

Promoter with highest holding

Pharmaceutical Business Group [india] Ltd (47.02%)

Highest Public shareholder

Quant Mutual Fund - Quant Manufacturing Fund (1.15%)

Individual Investors Holdings

19.75%

stock-summaryFinancial
[
  {
    "link": "quarterly",
    "btn_text": "All Quarterly Results",
    "header": "Quarterly Results Snapshot (Standalone) - Dec'24 - QoQ",
    "rhs": [
      {
        "prefix": "Net Sales ",
        "suffix": "QoQ Growth in quarter ended Dec 2024 is 13.82% vs -10.58% in Sep 2024",
        "dir": 1
      },
      {
        "prefix": "Standalone Net Profit ",
        "suffix": "QoQ Growth in quarter ended Dec 2024 is 22.71% vs -20.17% in Sep 2024",
        "dir": 1
      }
    ],
    "table": {
      "header": [
        "Dec'24",
        "Sep'24",
        "Change(%)"
      ],
      "body": [
        {
          "field": "Net Sales",
          "val1": "39.52",
          "val2": "34.72",
          "chgp": "13.82%",
          "chgp_class": "positive"
        },
        {
          "field": "Operating Profit (PBDIT) excl Other Income",
          "val1": "18.86",
          "val2": "15.40",
          "chgp": "22.47%",
          "chgp_class": "positive"
        },
        {
          "field": "Interest",
          "val1": "0.14",
          "val2": "0.08",
          "chgp": "75.00%",
          "chgp_class": "negative"
        },
        {
          "field": "Exceptional Items",
          "val1": "0.00",
          "val2": "0.00",
          "chgp": "",
          "chgp_class": "neutral"
        },
        {
          "field": "Standalone Net Profit",
          "val1": "12.97",
          "val2": "10.57",
          "chgp": "22.71%",
          "chgp_class": "positive"
        },
        {
          "field": "Operating Profit Margin (Excl OI)",
          "val1": "47.72%",
          "val2": "44.35%",
          "chgp": "3.37%",
          "chgp_class": "positive"
        }
      ]
    }
  },
  {
    "link": "half-yearly",
    "btn_text": "All Half Yearly Results",
    "header": "Half Yearly Results Snapshot (Standalone) - Sep'24",
    "rhs": [
      {
        "prefix": "Net Sales ",
        "suffix": " Growth in half year ended Sep 2024 is -17.40% vs -3.90% in Sep 2023",
        "dir": -1
      },
      {
        "prefix": "Standalone Net Profit ",
        "suffix": " Growth in half year ended Sep 2024 is -21.37% vs -17.00% in Sep 2023",
        "dir": -1
      }
    ],
    "table": {
      "header": [
        "Sep'24",
        "Sep'23",
        "Change(%)"
      ],
      "body": [
        {
          "field": "Net Sales",
          "val1": "73.54",
          "val2": "89.03",
          "chgp": "-17.40%",
          "chgp_class": "negative"
        },
        {
          "field": "Operating Profit (PBDIT) excl Other Income",
          "val1": "33.93",
          "val2": "40.13",
          "chgp": "-15.45%",
          "chgp_class": "negative"
        },
        {
          "field": "Interest",
          "val1": "0.15",
          "val2": "0.08",
          "chgp": "87.50%",
          "chgp_class": "negative"
        },
        {
          "field": "Exceptional Items",
          "val1": "0.00",
          "val2": "0.00",
          "chgp": "",
          "chgp_class": "neutral"
        },
        {
          "field": "Standalone Net Profit",
          "val1": "23.80",
          "val2": "30.27",
          "chgp": "-21.37%",
          "chgp_class": "negative"
        },
        {
          "field": "Operating Profit Margin (Excl OI)",
          "val1": "46.14%",
          "val2": "45.07%",
          "chgp": "1.07%",
          "chgp_class": "positive"
        }
      ]
    }
  },
  {
    "link": "nine-monthly",
    "btn_text": "All Nine Monthly Results",
    "header": "Nine Monthly Results Snapshot (Standalone) - Dec'24",
    "rhs": [
      {
        "prefix": "Net Sales ",
        "suffix": "YoY Growth in nine months ended Dec 2024 is -11.54% vs 5.79% in Dec 2023",
        "dir": -1
      },
      {
        "prefix": "Standalone Net Profit ",
        "suffix": "YoY Growth in nine months ended Dec 2024 is -15.04% vs -6.48% in Dec 2023",
        "dir": -1
      }
    ],
    "table": {
      "header": [
        "Dec'24",
        "Dec'23",
        "Change(%)"
      ],
      "body": [
        {
          "field": "Net Sales",
          "val1": "113.06",
          "val2": "127.81",
          "chgp": "-11.54%",
          "chgp_class": "negative"
        },
        {
          "field": "Operating Profit (PBDIT) excl Other Income",
          "val1": "52.79",
          "val2": "57.80",
          "chgp": "-8.67%",
          "chgp_class": "negative"
        },
        {
          "field": "Interest",
          "val1": "0.29",
          "val2": "0.16",
          "chgp": "81.25%",
          "chgp_class": "negative"
        },
        {
          "field": "Exceptional Items",
          "val1": "0.00",
          "val2": "0.00",
          "chgp": "",
          "chgp_class": "neutral"
        },
        {
          "field": "Standalone Net Profit",
          "val1": "36.77",
          "val2": "43.28",
          "chgp": "-15.04%",
          "chgp_class": "negative"
        },
        {
          "field": "Operating Profit Margin (Excl OI)",
          "val1": "46.69%",
          "val2": "45.22%",
          "chgp": "1.47%",
          "chgp_class": "positive"
        }
      ]
    }
  },
  {
    "link": "annual",
    "btn_text": "All Annual Results",
    "header": "Annual Results Snapshot (Standalone) - Mar'24",
    "rhs": [
      {
        "prefix": "Net Sales ",
        "suffix": "YoY Growth in year ended Mar 2024 is 14.44% vs 29.20% in Mar 2023",
        "dir": -1
      },
      {
        "prefix": "Standalone Net Profit ",
        "suffix": "YoY Growth in year ended Mar 2024 is 2.05% vs 32.90% in Mar 2023",
        "dir": -1
      }
    ],
    "table": {
      "header": [
        "Mar'24",
        "Mar'23",
        "Change(%)"
      ],
      "body": [
        {
          "field": "Net Sales",
          "val1": "169.82",
          "val2": "148.39",
          "chgp": "14.44%",
          "chgp_class": "positive"
        },
        {
          "field": "Operating Profit (PBDIT) excl Other Income",
          "val1": "78.74",
          "val2": "73.64",
          "chgp": "6.93%",
          "chgp_class": "positive"
        },
        {
          "field": "Interest",
          "val1": "0.23",
          "val2": "0.18",
          "chgp": "27.78%",
          "chgp_class": "negative"
        },
        {
          "field": "Exceptional Items",
          "val1": "0.00",
          "val2": "0.00",
          "chgp": "",
          "chgp_class": "neutral"
        },
        {
          "field": "Standalone Net Profit",
          "val1": "59.16",
          "val2": "57.97",
          "chgp": "2.05%",
          "chgp_class": "positive"
        },
        {
          "field": "Operating Profit Margin (Excl OI)",
          "val1": "46.37%",
          "val2": "49.63%",
          "chgp": "-3.26%",
          "chgp_class": "negative"
        }
      ]
    }
  }
]
Quarterly Results Snapshot (Standalone) - Dec'24 - QoQstock-summary
Dec'24
Sep'24
Change(%)
Net Sales
39.52
34.72
13.82%
Operating Profit (PBDIT) excl Other Income
18.86
15.40
22.47%
Interest
0.14
0.08
75.00%
Exceptional Items
0.00
0.00
Standalone Net Profit
12.97
10.57
22.71%
Operating Profit Margin (Excl OI)
47.72%
44.35%
3.37%
Values in Rs Cr.
stock-summary Compare with Peers
Direction Arrows
Net Sales

QoQ Growth in quarter ended Dec 2024 is 13.82% vs -10.58% in Sep 2024

Direction Arrows
Standalone Net Profit

QoQ Growth in quarter ended Dec 2024 is 22.71% vs -20.17% in Sep 2024

All Quarterly Resultsstock-summary
Half Yearly Results Snapshot (Standalone) - Sep'24stock-summary
Sep'24
Sep'23
Change(%)
Net Sales
73.54
89.03
-17.40%
Operating Profit (PBDIT) excl Other Income
33.93
40.13
-15.45%
Interest
0.15
0.08
87.50%
Exceptional Items
0.00
0.00
Standalone Net Profit
23.80
30.27
-21.37%
Operating Profit Margin (Excl OI)
46.14%
45.07%
1.07%
Values in Rs Cr.
stock-summary Compare with Peers
Direction Arrows
Net Sales

Growth in half year ended Sep 2024 is -17.40% vs -3.90% in Sep 2023

Direction Arrows
Standalone Net Profit

Growth in half year ended Sep 2024 is -21.37% vs -17.00% in Sep 2023

All Half Yearly Resultsstock-summary
Nine Monthly Results Snapshot (Standalone) - Dec'24stock-summary
Dec'24
Dec'23
Change(%)
Net Sales
113.06
127.81
-11.54%
Operating Profit (PBDIT) excl Other Income
52.79
57.80
-8.67%
Interest
0.29
0.16
81.25%
Exceptional Items
0.00
0.00
Standalone Net Profit
36.77
43.28
-15.04%
Operating Profit Margin (Excl OI)
46.69%
45.22%
1.47%
Values in Rs Cr.
stock-summary Compare with Peers
Direction Arrows
Net Sales

YoY Growth in nine months ended Dec 2024 is -11.54% vs 5.79% in Dec 2023

Direction Arrows
Standalone Net Profit

YoY Growth in nine months ended Dec 2024 is -15.04% vs -6.48% in Dec 2023

All Nine Monthly Resultsstock-summary
Annual Results Snapshot (Standalone) - Mar'24stock-summary
Mar'24
Mar'23
Change(%)
Net Sales
169.82
148.39
14.44%
Operating Profit (PBDIT) excl Other Income
78.74
73.64
6.93%
Interest
0.23
0.18
27.78%
Exceptional Items
0.00
0.00
Standalone Net Profit
59.16
57.97
2.05%
Operating Profit Margin (Excl OI)
46.37%
49.63%
-3.26%
Values in Rs Cr.
stock-summary Compare with Peers
Direction Arrows
Net Sales

YoY Growth in year ended Mar 2024 is 14.44% vs 29.20% in Mar 2023

Direction Arrows
Standalone Net Profit

YoY Growth in year ended Mar 2024 is 2.05% vs 32.90% in Mar 2023

All Annual Resultsstock-summary
stock-summaryCompany CV
About Gujarat Themis Biosyn Ltd stock-summary
stock-summary
Gujarat Themis Biosyn Ltd
Small Cap
Pharmaceuticals & Drugs
Promoted by Kantilal Shah, Gujarat Themis Biosyn Limited was incorporated in 1981 as a joint sector company with Gujarat Industrial Investment Corporation Ltd (GIIC) and Chemosyn (P) Ltd. The Company commenced production in August 1985. It was subsequently taken over in June 1991 by Yuhan Group, South Korea and Pharmaceutical Business Group (India) Ltd. (PBG); a unique consortium of five competing drug companies - Themis Medicare Ltd., Kopran Ltd., Anant & Co., Cadila Health Care Ltd.
Company Coordinates stock-summary
Company Details
69/C GIDC Industrial Estate, Valsad Dist VAPI Gujarat : 396195
stock-summary
Tel: 91-260-2430027
stock-summary
http://www.gtbl.in
stock-summary
accounts@gtbl.co.in/gtblmumbai@gtbl
Registrar Details
Link Intime India Pvt Ltd, C-13 Pannalal Silk Compound, L B S Marg, Bhandup , Mumbai
Stock List
ABCDEFGHIJKLMNOPQRSTUVWXYZOther
Footer Logo
InfinHub Market Technologies FZ-LLC, Building-2, Unit 112, Dubai Internet City, Dubai, United Arab Emirates
GET THE MARKETSMOJO APP
Company
Stocks
Portfolio
Market
Webinars
"Investment in securities markets are subject to market risk. Read all the related documents carefully before investing."